乳がん治療薬市場- 治療別、2023～2032年世界予測

世界の乳がん治療薬市場は、乳がん領域における新規事象や活発な研究開発によって後押しされ、2023年から2032年にかけてCAGR7.3%を記録します。

新たな研究が革新的な治療法を発見し、先進的な治療オプションの需要を促進します。

例えば、2023年12月に開催された2023 San Antonio Breast Cancer Symposium（SABCS）では、転移性乳がん患者の予後改善や治療抵抗性についての洞察を提供する治験的治療法にスポットが当てられました。そのような研究の1つであるHER2CLIMB-02試験では、トラスツズマブエムタンシン（T-DM1）療法にツカチニブを組み込むことで、治療歴のあるHER2陽性の転移性または局所進行乳がん患者の無増悪生存期間（PFS）が延長することが明らかになった。精密医療、免疫療法、標的治療におけるブレークスルーは、より効果的で個別化された乳がん治療に対するニーズの高まりに対応し、市場の成長を増幅させる。科学的発見と進化する事象のダイナミックな情勢により、市場は乳がんとの闘いにおける治療成績の改善と治療法の強化の絶え間ない探求に応えています。

化学療法分野の市場規模は、2023年から2032年にかけて顕著なCAGRを記録します。標的療法の進歩にもかかわらず、化学療法は、特に侵攻性のがん種においてその重要性を維持しています。ネオアジュバント療法やアジュバント療法における化学療法の役割は、新たな併用療法と並んで需要を支えています。副作用を最小限に抑え、有効性を高めるために改良が続けられている化学療法は、多様な患者プロファイルのニーズに応え、極めて重要な地位を維持しています。乳がん治療における化学療法の永続的な役割は、患者の包括的なケアと治療の選択肢を確保し、治療薬市場における需要を引き続き促進しています。

アジア太平洋地域の乳がん治療薬産業は、2023年から2032年にかけて顕著なCAGRを示すと思われます。アジア太平洋地域で乳がんの罹患率が急増する中、革新的な治療法や先進的な治療オプションが重視されるようになっています。ヘルスケアシステムの進化や個別化医療へのシフトに伴い、標的療法や最先端治療への需要が高まっています。この急成長する市場は、アジア太平洋地域の予後改善への探求に対応し、アジア太平洋のヘルスケア領域における乳がん治療薬のダイナミックな展望を育んでいます。

例えば、2023年12月、ファイザー、モナシュ大学、オーストラリアのCancer Therapeutics Cooperative Research Centreの共同研究により、エストロゲン受容体（ER）陽性乳がんに対する前臨床薬の可能性が発見されました。この研究により、経口で生物学的に利用可能な「KAT6A/B」阻害剤であるCTx-648が発見され、顕著な選択性と効力を示しました。マウスモデルにおいて、CTx-648はER陽性乳がんにおいて、ホルモン療法に抵抗性を示す症例においても有意な抗腫瘍効果を示しました。この画期的な結果は、ER陽性乳がんにおけるKAT6Aを標的とする新たな展望をもたらし、患者に新たな治療手段を提供する可能性があります。

目次

第1章 調査手法と調査範囲

第2章 エグゼクティブサマリー

第3章 乳がん治療薬市場の洞察

• 業界情勢
• 業界への影響要因
  • 促進要因
    • 乳がんの負担増
    • 研究開発への投資の増加
    • 複数の診断およびスクリーニングプログラムの開始
    • 有利な保険および償還政策
  • 業界の潜在的リスク＆課題
    • 乳がん治療薬に伴う副作用
    • 薬剤費の高騰
  • 成長可能性分析
  • 治療法別
• COVID-19の影響分析
• 規制状況
• ポーター分析
• PESTEL分析

第4章 競合情勢

• イントロダクション
• 企業マトリックス分析
• 主要市場プレーヤーの競合分析
• 競合のポジショニングマトリックス
• 戦略ダッシュボード

第5章 乳がん治療薬市場推計・予測：治療別、2018年～2032年

• 主要動向：療法別
• 標的療法
• ホルモン療法
• 化学療法
• 免疫療法

第6章 乳がん治療薬市場推計・予測：地域別、2018年～2032年

• 主要動向：地域別
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • オーストラリア
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • その他中東とアフリカ

第7章 企業プロファイル

• AstraZeneca plc.
• Eli Lilly & Co, Inc.
• Pfizer, Inc.
• Novartis AG
• Amgen
• F. Hoffmann La Roche AG
• Merck & Co, Inc.
• Gilead Sciences, Inc.
• Eisai Co., Ltd.
• Macrogenics, Inc.
• Stemline Therapeutics, Inc.

Data Tables

• TABLE 1 Market revenue, by therapy (2022)
• TABLE 2 Market share, by region (2022)
• TABLE 3 Global breast cancer therapeutics market size, by region, 2018 - 2022 (USD Million)
• TABLE 4 Global breast cancer therapeutics market size, by region, 2023 - 2032 (USD Million)
• TABLE 5 Global breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 6 Global breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 7 Industry impact forces
• TABLE 8 Targeted therapy market size, 2018 - 2022 (USD Million)
• TABLE 9 Targeted therapy market size, 2023 - 2032 (USD Million)
• TABLE 10 Hormonal therapy market size, 2018 - 2022 (USD Million)
• TABLE 11 Hormonal therapy market size, 2023 - 2032 (USD Million)
• TABLE 12 Chemotherapy market size, 2018 - 2022 (USD Million)
• TABLE 13 Chemotherapy market size, 2023 - 2032 (USD Million)
• TABLE 14 Immunotherapy market size, 2018 - 2022 (USD Million)
• TABLE 15 Immunotherapy market size, 2023 - 2032 (USD Million)
• TABLE 16 North America breast cancer therapeutics market size, by country, 2018 - 2022 (USD Million)
• TABLE 17 North America breast cancer therapeutics market size, by country, 2023 - 2032 (USD Million)
• TABLE 18 North America breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 19 North America breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 20 U.S. breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 21 U.S. breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 22 Canada breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 23 Canada breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 24 Europe breast cancer therapeutics market size, by country, 2018 - 2022 (USD Million)
• TABLE 25 Europe breast cancer therapeutics market size, by country, 2023 - 2032 (USD Million)
• TABLE 26 Europe breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 27 Europe breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 28 Germany breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 29 Germany breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 30 UK breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 31 UK breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 32 France breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 33 France breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 34 Spain breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 35 Spain breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 36 Italy breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 37 Italy breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 38 Rest of Europe breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 39 Rest of Europe breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 40 Asia Pacific breast cancer therapeutics market size, by country, 2018 - 2022 (USD Million)
• TABLE 41 Asia Pacific breast cancer therapeutics market size, by country, 2023 - 2032 (USD Million)
• TABLE 42 Asia Pacific breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 43 Asia Pacific breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 44 China breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 45 China breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 46 Japan breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 47 Japan breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 48 India breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 49 India breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 50 Australia breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 51 Australia breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 52 Rest of Asia Pacific breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 53 Rest of Asia Pacific breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 54 Latin America breast cancer therapeutics market size, by country, 2018 - 2022 (USD Million)
• TABLE 55 Latin America breast cancer therapeutics market size, by country, 2023 - 2032 (USD Million)
• TABLE 56 Latin America breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 57 Latin America breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 58 Brazil breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 59 Brazil breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 60 Mexico breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 61 Mexico breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 62 Rest of Latin America breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 63 Rest of Latin America breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 64 Middle East & Africa breast cancer therapeutics market size, by country, 2018 - 2022 (USD Million)
• TABLE 65 Middle East & Africa breast cancer therapeutics market size, by country, 2023 - 2032 (USD Million)
• TABLE 66 Middle East & Africa breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 67 Middle East & Africa breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 68 South Africa breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 69 South Africa breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 70 Saudi Arabia breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 71 Saudi Arabia breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
• TABLE 72 Rest of Middle East & Africa breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
• TABLE 73 Rest of Middle East & Africa breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)

Charts & Figures

• FIG 1 GMI report coverage: Critical research elements
• FIG 2 Top-down approach
• FIG 3 Market estimation and forecast methodology
• FIG 4 Market forecasting methodology
• FIG 5 Breakdown of primary participants
• FIG 6 Breast cancer therapeutics industry 360 degree synopsis, 2018 - 2032
• FIG 7 Growth potential analysis, By Therapy
• FIG 8 Porter's analysis
• FIG 9 PESTEL analysis
• FIG 10 Company matrix analysis, 2022
• FIG 11 Competitive analysis of major market players, 2022
• FIG 12 Competitive positioning matrix, 2022
• FIG 13 Strategic dashboard, 2022

Global Breast Cancer Therapeutics Market will witness 7.3% CAGR between 2023 and 2032 propelled by novel events and robust research and development within the breast cancer domain. Emerging studies uncover innovative therapies, driving demand for advanced treatment options.

For instance, in December 2023, at the 2023 San Antonio Breast Cancer Symposium (SABCS), research spotlighted investigational treatments offering improved outcomes for metastatic breast cancer patients and insights into treatment resistance. One such research, The HER2CLIMB-02 trial revealed that incorporating tucatinib into trastuzumab emtansine (T-DM1) therapy extended progression-free survival (PFS) among individuals with previously treated HER2-positive metastatic or locally advanced breast cancer. Breakthroughs in precision medicine, immunotherapy, and targeted therapies amplify market growth, meeting the escalating need for more effective and personalized breast cancer treatments. With a dynamic landscape of scientific discoveries and evolving events, the market responds to the continuous quest for improved outcomes and enhanced therapies in the fight against breast cancer

The overall Breast Cancer Therapeutics Market share is classified based on therapy, and region.

The market size from the chemotherapy segment will register a noteworthy CAGR from 2023 to 2032. Despite advancements in targeted therapies, chemotherapy retains its significance, especially in aggressive cancer types. Its role in neoadjuvant and adjuvant settings, alongside emerging combination therapies, sustains demand. With ongoing refinements to minimize side effects and enhance efficacy, chemotherapy maintains a pivotal stance, meeting the needs of diverse patient profiles. Its enduring role in breast cancer treatment continues to fuel demand within the therapeutics market, ensuring comprehensive care and treatment options for patients.

Asia Pacific breast cancer therapeutics industry will showcase a commendable CAGR from 2023 to 2032. rising incidences and a growing focus on healthcare infrastructure. As breast cancer rates surge across Asia Pacific, there's an increased emphasis on innovative therapies and advanced treatment options. With evolving healthcare systems and a shift toward personalized medicine, the demand for targeted therapies and cutting-edge treatments rises. This burgeoning market caters to the region's quest for improved outcomes, fostering a dynamic landscape of breast cancer therapeutics within Asia Pacific's healthcare domain.

For instance, in December 2023, A collaborative effort between Pfizer, Monash University, and the Cancer Therapeutics Cooperative Research Centre, in Australia uncovered a potential pre-clinical drug for Estrogen Receptor (ER) positive breast cancer. This study unveiled CTx-648, an orally bioavailable 'KAT6A/B' inhibitor showing remarkable selectivity and potency. In mouse models, CTx-648 demonstrated significant anti-tumor effects in ER-positive breast cancer, even in cases resistant to hormone therapy. This breakthrough introduces a new prospect for targeting KAT6A in ER-positive breast cancer, potentially offering a novel treatment avenue for patients.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Forecast Calculation
• 1.4 Covid-19 impact analysis at global level
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Breast cancer therapeutics industry 360 degree synopsis, 2018 - 2032 (USD Million)
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Therapy trends

Chapter 3 Breast Cancer Therapeutics Market Insights

• 3.1 Industry landscape, 2018 - 2032 (USD Million)
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing burden of breast cancer
    • 3.2.1.2 Increasing investments in R&D
    • 3.2.1.3 Launch of several diagnostic and screening programs
    • 3.2.1.4 Favorable insurance and reimbursement policies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse-effects associated with breast cancer drugs
    • 3.2.2.2 High cost of drugs
  • 3.2.3 Growth potential analysis
  • 3.2.4 By therapy
• 3.3 COVID-19 impact analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis, 2022
• 4.3 Competitive analysis of major market players, 2022
• 4.4 Competitive positioning matrix, 2022
• 4.5 Strategic dashboard, 2022

Chapter 5 Breast Cancer Therapeutics Market Estimates and Forecast, By Therapy, 2018-2032 (USD Million)

• 5.1 Key trends, by therapy
• 5.2 Targeted therapy
• 5.3 Hormonal therapy
• 5.4 Chemotherapy
• 5.5 Immunotherapy

Chapter 6 Breast Cancer Therapeutics Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)

• 6.1 Key trends, by region
• 6.2 North America
  • 6.2.1 U.S.
  • 6.2.2 Canada
• 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 UK
  • 6.3.3 France
  • 6.3.4 Spain
  • 6.3.5 Italy
  • 6.3.6 Rest of Europe
• 6.4 Asia Pacific
  • 6.4.1 China
  • 6.4.2 Japan
  • 6.4.3 India
  • 6.4.4 Australia
  • 6.4.5 Rest of Asia Pacific
• 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Mexico
  • 6.5.3 Rest of Latin America
• 6.6 Middle East & Africa
  • 6.6.1 South Africa
  • 6.6.2 Saudi Arabia
  • 6.6.3 Rest of Middle East & Africa

Chapter 7 Company Profiles

• 7.1 AstraZeneca plc.
• 7.2 Eli Lilly & Co, Inc.
• 7.3 Pfizer, Inc.
• 7.4 Novartis AG
• 7.5 Amgen
• 7.6 F. Hoffmann La Roche AG
• 7.7 Merck & Co, Inc.
• 7.8 Gilead Sciences, Inc.
• 7.9 Eisai Co., Ltd.
• 7.10 Macrogenics, Inc.
• 7.11 Stemline Therapeutics, Inc.